News

Hashad is a retinal specialist with over 25 years of leadership experience in global research and development.

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported

4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.

The event will include presentations on artificial intelligence, ocular imaging and surgical topics.

A total of 43 patients who recovered from the SARS-CoV-2 infection with mild pneumonia were included along with 45 healthy individuals.

Visual acuity with both approaches was comparable and the device was efficacious and safe.

This database could enhance the workflow of eye care professionals with its in-depth reference data for retinal layer thickness and optic nerve head metrics.

The findings were from 6 patients in the first low-dose cohort of the ongoing first-in-human trial (NCT04627428).

Retina Resource was developed by retina specialists for retina specialists.

ABI-201 aims to prevent dry AMD and other retinal disorders in patients.

The modifier gene therapies from Ocugen target geographic atrophy and Stargardt disease.

The data was included in the paper, titled “Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type.”

Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette and is designed to be administered as a one-time intravitreal injection.

PYK-2101 is a first-in-class biodegradable retinal hydrogel sealant.

Apellis Pharmaceuticals and EyePoint Pharmaceuticals are both scheduled to present at the conference.

If approved, the drug will be branded as LYTENAVA.

This follows successful Phase 1 results, which demonstrated a favorable safety profile for BI 771716 across both single and multiple intravitreal doses.

The company also reported a positive outcome of an analysis of masked data from its ongoing MAGNIFY Phase 2 trial for zervimesine in adults with GA.

This device is designed to assist healthcare professionals in analyzing fundus images for the early detection of key retinal conditions.

Researchers indicated that pediatric patients with Leber congenital amaurosis experienced improvements in vision.

The intent is that the board provide strategic guidance and expert insights to support the development of the company’s programs and science.

The biosimilar to aflibercept (Eylea) had already received approval in the EU and US.

RPESC-RPE-4W is a cell product derived from adult retinal pigment epithelial stem cells.

Risk factors vary in both short-term and long-term periods following Boston Type 1 keratoprosthesis surgery.

Arctic Vision has a commercial collaboration agreement with Santen Pharmaceutical Co., Ltd. to commercialize ARVN001 for the treatment of UME.

The researchers successfully tested the robot using enucleated pig eyes.

The imaging system is designed to enable secure, real-time remote monitoring around the clock, from virtually any location.